Clinical Trials · NCT02867267
The Efficacy and Safety of Ta1 for Sepsis
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sun Yat-sen University
- Enrollment
- 1,106
- Start date
- Sep 2016
- Locations
- 22 sites, China
- Primary endpoint
- 28-day all-cause mortality